Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia.
AuthorsNiemeyer, Charlotte M
Loh, Mignon L
Dvorak, Christopher C
De Moerloose, Barbara
Smith, Owen P
van den Heuvel-Eibrink, Marry M
AffiliationOur Ladys Hospital Crumin, Dublin
Clinical Trials as Topic
Combined Modality Therapy
Leukemia, Myelomonocytic, Juvenile
Neoplasm Recurrence, Local
Practice Guidelines as Topic
MetadataShow full item record
CitationCriteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia. 2015, 100 (1):17-22 Haematologica
AbstractJuvenile myelomonocytic leukemia is a rare myeloproliferative disease in young children. While hematopoietic stem cell transplantation remains the only curative therapeutic option for most patients, children with juvenile myelomonocytic leukemia increasingly receive novel agents in phase I-II clinical trials as pre-transplant therapy or therapy for relapse after transplantation. However, response criteria or definitions of outcome for standardized evaluation of treatment effect in patients with juvenile myelomonocytic leukemia are currently lacking. Here we propose criteria to evaluate the response to the non-transplant therapy and definitions of remission status after hematopoietic stem cell transplantation. For the evaluation of non-transplant therapy, we defined 6 clinical variables (white blood cell count, platelet count, hematopoietic precursors and blasts in peripheral blood, bone marrow blast percentage, spleen size and extramedullary disease) and 3 genetic variables (cytogenetic, molecular and chimerism response) which serve to describe the heterogeneous picture of response to therapy in each individual case. It is hoped that these criteria will facilitate the comparison of results between clinical trials in juvenile myelomonocytic leukemia.
- Combination of DNA-hypomethylating agent and hematopoietic stem cell transplantation in treatment of juvenile myelomonocytic leukemia: A case report.
- Authors: Ai Y, Lu X, Zhu T, Zhu Y, Liu H, Sun S
- Issue date: 2020 Dec 11
- [Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia].
- Authors: Shao Q, Wang ZD, Zheng XL, Dong L, Han DM, Yan HM, Wang HX, Duan LN
- Issue date: 2014 Aug
- Diagnosis and treatment of juvenile myelomonocytic leukemia.
- Authors: Sakashita K, Matsuda K, Koike K
- Issue date: 2016 Aug
- Diagnosis and treatment of juvenile myelomonocytic leukemia in Slovak Republic: novel approaches.
- Authors: Fabri O, Horakova J, Bodova I, Svec P, Laluhova Striezencova Z, Bubanska E, Cermak M, Galisova V, Skalicka K, Vaska A, Doczyova D, Panikova A, Sykora T, Adamcakova J, Kolenova A
- Issue date: 2019 May 11
- Clinical course of juvenile myelomonocytic leukemia in the blast crisis phase treated by acute myeloid leukemia-oriented chemotherapy and allogeneic hematopoietic stem cell transplantation.
- Authors: Ueda S, Sakata N, Muramatsu H, Sakaguchi H, Wang X, Xu Y, Kojima S, Yamaguchi T, Higa T, Takemura T
- Issue date: 2014 Nov